Recursion Pharmaceuticals: A Calculated Risk

Recursion Pharmaceuticals (RXRX +11.80%) is, ostensibly, attempting to provide that tool. Their “Recursion OS” platform, built on a vast database – 65 petabytes, they claim, which is a figure designed more to impress than to inform – aims to virtually test drug candidates. The implication is that years of laboratory work and millions in expenditure can be reduced, if not eliminated. It is a bold claim, and one should approach it with a degree of skepticism.








